{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-24-000090","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.606860+00:00","generated_at":"2026-05-31T09:42:37.117817+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acumen Q2 net loss expands to $20.5M; Phase 2 AD trial enrollment ahead of expectations","bullets":["Net loss $20.5M in Q2 2024 vs $11.6M in Q2 2023; R&D spending rose to $19.5M (from $9.1M) on ALTITUDE-AD costs.","Cash, equivalents, and securities $281.4M at June 30, 2024 (down from $306.1M at Dec 31, 2023); runway into H1 2027.","Phase 2 ALTITUDE-AD enrollment faster than expected; over 50 sites activated in U.S., Canada, U.K., EU.","Phase 1 subcutaneous sabirnetug study dosed first subject July 2024; topline data expected Q1 2025.","Virtual R&D Day planned Oct 2, 2024, to detail sabirnetug science and Phase 1 results."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-24-000090","json":"https://secwatch.observer/filing/0001576885-24-000090.json","markdown":"https://secwatch.observer/filing/0001576885-24-000090.md","text":"https://secwatch.observer/filing/0001576885-24-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000090/0001576885-24-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000090/abos-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:42:37.117817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}